

## Business Offer

# Catalogue of non-exclusive intermediates to support pharmaceutical research offered under services agreement

## Summary

*A UK company has a catalogue of intermediates which can be used for the design & synthesis of novel compounds and offer a variety of customised commercial frameworks. They seeking partners to acquire these compounds and can supply them to researchers or companies in large amounts with a relatively short lead-time. They are seeking service or acquisition agreements with pharmaceutical or drug development companies/researchers interested in using these intermediates for new co-developed products.*

<b>Creation Date</b>	21 July 2016
<b>Last Update</b>	08 February 2018
<b>Expiration Date</b>	11 August 2018
<b>Reference</b>	BOUK20160721002
<b>Public Link</b>	<a href="https://een.ec.europa.eu/tools/services/PRO/Profile/Detail/a5b332d3-3ea5-46bc-ba65-afb9bacf075e">https://een.ec.europa.eu/tools/services/PRO/Profile/Detail/a5b332d3-3ea5-46bc-ba65-afb9bacf075e</a>

## Details

### Description

The intermediates catalogue provides access to a wide variety of practical building blocks, many of which are unique to the company. The UK company supply all of these compounds in research quantities from stock, while the company's kilo lab facility offers many of these intermediates in 100g-1kg lots with lead times of only 4-6 weeks.

In addition to the company's in-house developments, and in order to drive diversity and novelty in their customers' drug discovery programmes, the company fosters strategic collaborations that add new ranges to the intermediates catalogue.

They are seeking pharmaceutical and drug development companies and/or researchers for acquisition agreements or services agreements, to supply these products to new partners and co-develop new intermediates with new clients.

For example, a previous collaboration with a catalyst technology company resulted in the development of a series of spirodiamine compounds. Such spirodiamines have been shown to be useful in the construction of novel pharmaceutically relevant investigative compounds.

The company also offers a variety of customised commercial frameworks, from simple fee-for-

service right through to long-term FTE (full-time equivalent) projects. They are trusted by major pharma & biotech companies and operate an embedded team of FTE scientists inside the client's facility on a long-term basis.

The company has a significant array of assets for small molecule discovery and has all the essential hardware for modern organic and computational chemistry, a purpose-built ADMET (absorption, distribution, metabolism, excretion and toxicity) lab with cell culture facilities, scale-up laboratories, automated purification to support array synthesis and a highly engineered suite for pressure chemistry.

They are also available to offer their services towards any existing H2020 bids that might be relevant.

## Advantages and Innovations

The intermediates catalogue provides a large variety of practical building blocks, many of which are unique to the company. They can be supplied in research quantities from stock, while the kilo lab facility allows the company to offer many of these intermediates in 100g-1kg lots with lead times of 4-6 weeks.

The company was founded in 1992 and is now considered a leading CRO (contract research organisation) in the UK.

Using its heritage in the supply of rational building blocks for medicinal chemistry, biased screening libraries and custom synthesis as a springboard, the company now operates a comprehensive suite of services for hit-to-lead and lead optimisation studies. The company's workforce consists of over 85% PhD-level scientists, and the company has a purpose-built lab with cell culture facilities, scale-up laboratories with vessels up to 50L, automated purification to support array synthesis and a highly engineered suite for pressure chemistry.

## Profile Origin

Other

---

## Keywords

### Market

05007002	Pharmaceuticals/fine chemicals
05007007	Other medical/health related (not elsewhere classified)

### NACE

M.72.1.1	Research and experimental development on biotechnology
M.74.9.0	Other professional, scientific and technical activities n.e.c.
Q.86.9.0	Other human health activities

---

## Network Contact

### Issuing Partner

ASTER - SOCIETA CONSORTILE PER AZIONI

Ref: BOUK20160721002

---

**Contact Person**

Vera Lullo

**Phone Number**

+39 0516398090

**Email**

vera.lullo@aster.it

---

**Open for EOI :** **Yes**

---

**Dissemination****Send to Sector Group**

Bio Chem Tech

---

**Client****Type and Size of Organisation Behind the Profile**

Industry SME 50-249

**Year Established**

1992

**Turnover**

50 - 100M

**Already Engaged in Trans-National Cooperation**

Yes

**Languages Spoken**

English

**Client Country**

United Kingdom

---

**Partner Sought****Type and Role of Partner Sought**

Type of partner: Industry/academia

Activity of partner: Drug development

Ref: BOUK20160721002

Role of partner in this offer: The co-development of novel pharmaceutical products from the intermediates, which can be used to design and synthesise novel compounds, or the acquisition of intermediates for use.

## **Type and Size of Partner Sought**

SME 11-50, University, Inventor, R&D Institution, SME <10,>500 MNE, 251-500, SME 51-250

## **Type of Partnership Considered**

Services agreement  
Acquisition agreement

---

## **Attachments**

---

## Technology Offer

---

# Proteomic fingerprinting as a rapid and cost-effective tool for the identification and traceability of fishery products

---

### Summary

---

*A German SME, offers proteomic techniques as a service for the identification of commercial fish, seeks research and business cooperations with the industry to apply the method to a wider field of products and uses and optionally refine methodological procedures. Proteome fingerprinting benefits over classical methods (as DNA-based tools) in time, costs and quality analytical standards. Targeted types of cooperation are technical agreements and commercial agreements with tech. assistance.*

<b>Creation Date</b>	19 September 2017
<b>Last Update</b>	26 September 2017
<b>Expiration Date</b>	26 September 2018
<b>Reference</b>	TODE20170919001
<b>Public Link</b>	<a href="https://een.ec.europa.eu/tools/services/PRO/Profile/Detail/77c1bf41-82d5-4b07-a4e5-a6b90e54c018">https://een.ec.europa.eu/tools/services/PRO/Profile/Detail/77c1bf41-82d5-4b07-a4e5-a6b90e54c018</a>

---

### Details

---

#### Description

The German start up applies proteomic techniques, the so called matrix-assisted laser desorption / ionization time-of-flight mass spectrometry (MALDI-TOF MS) to clearly determine fresh and processed fishery products, which provides a time- and cost effective methodology to guarantee the identity of seafood.

The start up offers a unique identification service to meet EU standards for fish and fishery products. A full service is ensured including high-quality analyses, competent expert consultation, and confidential treatment of the data as well as consideration of individual needs. The method is based on the knowledge that species can be separated on the basis of their proteomic signatures. The goal is to establish proteomic fingerprinting as a standard identification method for seafood, which will address socio-economic as well as conservational requirements alike.

The start up seeks to collaborate with partners from the seafood industry as well as research institutes in the field of fisheries and biodiversity research to design pilot studies and establish a work flow. The vision is to apply this method to a broad array of multi-celled organisms (incl. plants, meat products), so the start up also seeks collaboration with representatives from animal production, agriculture and forestry.

## Advantages and Innovations

For the client, proteome fingerprinting will be a straight forward, low-cost and a rapid way to distinguish fish products from another. The only requirement is a small amount of tissue of the target product, either fresh, in ethanol or deep frozen. Results will then be achieved within one day constituting less than half of the costs of previous DNA-based identifications.

The team is comprised of marine scientist with a long expertise in the molecular identification of species across a wide range of organisms, and can thus provide hands-on experience and competent advice as well as a clear interpretation of the results.

## Stage of Development

Already on the market

## IPR Status

Secret Know-how

## Profile Origin

Other

---

## Keywords

### Technology

06002002	Cellular and Molecular Biology
07001002	Animal Production / Husbandry
07002004	Silviculture, Forestry
07003001	Aquaculture
08002004	Traceability of food

### Market

09005	Agriculture, Forestry, Fishing, Animal Husbandry & Related Products
-------	---

### NACE

M.72.1.9	Other research and experimental development on natural sciences and engineering
----------	---

---

## Network Contact

### Issuing Partner

ASTER - SOCIETA CONSORTILE PER AZIONI

### Contact Person

Vera Lullo

### Phone Number

+39 0516398090

Ref: TODE20170919001

---

**Email**

vera.lullo@aster.it

---

**Open for EOI :**    **Yes**

---

**Dissemination**

---

**Send to Sector Group**

Maritime Industry and Services

---

**Client**

---

**Type and Size of Organisation Behind the Profile**

Industry SME <= 10

**Year Established**

0

**Already Engaged in Trans-National Cooperation**

No.

**Languages Spoken**

English  
German

**Client Country**

Germany

---

**Partner Sought**

---

**Type and Role of Partner Sought**

Industrial seafood companies, as well as companies with representatives from animal production, agriculture and forestry to apply the method to a wider field of products and uses and optionally refine methodological procedures.

**Type and Size of Partner Sought**

SME 11-50, University, R&D Institution, SME <10, >500 MNE, 251-500, SME 51-250, >500

**Type of Partnership Considered**

Commercial agreement with technical assistance  
Technical cooperation agreement

---

## Attachments

---



## Technology Request

---

# Therapeutic innovations for diseases of the nervous system with high unmet medical needs

---

### Summary

---

*A French pharmaceutical company is specialized in developing innovative treatments for diseases of the nervous system with high unmet medical needs. Within the frame of its development as fully integrated pharmaceutical company, it is currently looking for new assets for its portfolio in the field of neurological disorders. This company is considering license and/or research cooperation agreement as well as joint-venture agreement.*

<b>Creation Date</b>	05 September 2017
<b>Last Update</b>	02 October 2017
<b>Expiration Date</b>	02 October 2018
<b>Reference</b>	TRFR20170905001
<b>Public Link</b>	<a href="https://een.ec.europa.eu/tools/services/PRO/Profile/Detail/28fd7d56-50a2-43f9-b0a9-918643efa2a8">https://een.ec.europa.eu/tools/services/PRO/Profile/Detail/28fd7d56-50a2-43f9-b0a9-918643efa2a8</a>

---

### Details

---

#### Description

A French pharmaceutical company specialized in neurological diseases with high unmet medical needs. Its core focus lies on the metabolic alterations of central nervous system diseases as novel therapeutic approach.

The company's pipeline is currently composed of one molecule that has successfully finished phase III, two further compounds in late preclinical development and they have their own research platform to identify further promising therapeutic targets.

Within the frame of their development as fully integrated pharmaceutical company, it is now looking for new assets for the extension of its portfolio in the field of central nervous system disorders with high unmet medical needs. It is interested in new best- or first-in-class assets (new chemical entity, biologicals, repurposed drugs) preferentially targeting brain metabolism from early developmental stages (drug discovery) to late clinical phases. With its track record of successfully developed molecules and its expertise to progress the development of drugs from discovery to commercialisation, it is able to provide new treatment solutions for patients in need.

The French company is flexible concerning deal structure and is opened to different types of partnerships including in-licensing, co-development, research and development collaboration or sponsored research with both industrial and academic partners.

#### Technical Specification or Expertise Sought

Ref: TRFR20170905001

Research institutes, hospital or biotechnological and pharmaceutical companies with therapeutic assets that are looking for a partner to develop the molecules through preclinical and clinical stages towards commercialisation.

---

## Keywords

---

### Technology

06001012	Medical Research
06001014	Neurology, Brain Research
06001015	Pharmaceutical Products / Drugs
06001016	Physiology

### Market

05003001	Therapeutic services
----------	----------------------

### NACE

Q.86.9.0	Other human health activities
----------	-------------------------------

---

## Network Contact

---

### Issuing Partner

ASTER - SOCIETA CONSORTILE PER AZIONI

### Contact Person

Vera Lullo

### Phone Number

+39 0516398090

### Email

vera.lullo@aster.it

---

**Open for EOI :** **Yes**

---

---

## Dissemination

---

### Send to Sector Group

Healthcare

### Restrict Dissemination to Specific Countries

Albania, Argentina, Armenia, Austria, Belarus, Belgium,  
BosniaandHerzegovina, Brazil, Bulgaria, Cameroon, Canada, Chile,  
China, Croatia, Cyprus, CzechRepublic, Denmark, Egypt, Estonia,  
Finland, France, Georgia, Germany, Greece, Hungary, Iceland,  
India, Indonesia, Ireland, Israel, Italy, Japan, Jordan, Latvia,  
Lithuania, Luxembourg, Macedonia, TheformerYugoslavRepublicof, Malta,  
Mexico, Moldova, Montenegro, Netherlands, NewZealand, Norway,  
Paraguay, Peru, Poland, Portugal, Romania, Russia, Serbia,  
Singapore, Slovakia, Slovenia, SouthKorea, Spain, Sweden,  
Switzerland, Taiwan, Tunisia, Turkey, Ukraine,

---

## Client

---

### Type and Size of Organisation Behind the Profile

Industry SME 50-249

### Year Established

0

### Already Engaged in Trans-National Cooperation

No.

### Languages Spoken

English  
German  
French  
Italian

### Client Country

France

---

## Partner Sought

---

### Type and Role of Partner Sought

Industrial and academic partners, open for licensing, co-development, sponsored research with a pharmaceutical company

### Type of Partnership Considered

License agreement  
Joint venture agreement  
Research cooperation agreement

---

## Attachments

---